VolitionRx Demonstrates NuQ® Blood Test Detects 95% of Pancreatic Cancers in Second Preliminary Study - Introduction to VolitionRx Nucleosomics® technology: Revolutionizing cancer diagnosis
VolitionRx’s Nucleosomics® diagnostic platform detects epigenetic changes to fragments of chromosomes, called nucleosomes, that circulate in the blood of cancer patients. Credit: VolitionRx.